WC
HAE icon

Wexford Capital’s Haemonetics HAE Stock Holding History

Wexford Capital’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-40,138
Closed -$4.46M – 192
2021
Q1 		$4.46M Buy
40,138
+37,082
+1,213% +$4.59M 0.67% 36
2020
Q4 		$363K Buy
+3,056
New +$329K 0.06% 140

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
LCOV
London Company of Virginia Richmond, Virginia $16.2B AUM 17.5% 1-Year Est. Return
LCP
LGT Capital Partners Pfaeffikon, Switzerland $1.88B AUM 20.37% 1-Year Est. Return

Wexford Capital's HAE Position: Q2 2021 in Review

Wexford Capital sold out of Haemonetics (HAE) in Q2 2021, closing a stake of 40,138 shares — an estimated $4.46M sold.

Wexford Capital first reported a position in HAE in Q4 2020 and held it in 2 quarters. The position peaked at $4.46M in Q1 2021. 258 funds tracked by Wall St. Rank hold HAE as of Q2 2021.

  • Wexford Capital reported no remaining Haemonetics position as of Q2 2021 after selling out during the quarter.
  • Wexford Capital sold 40,138 Haemonetics shares in Q2 2021, an estimated $4.46M.
  • Wexford Capital first reported a position in Haemonetics in Q4 2020 and held it in 2 quarters.
  • Wexford Capital's Haemonetics position peaked at $4.46M in Q1 2021.
  • 258 funds tracked by Wall St. Rank held Haemonetics as of Q2 2021.

Based on Wexford Capital's 13F filing for Q2 2021, filed 16 Aug 2021.